New pill takes on Hard-to-Treat cancers in first human trial

NCT ID NCT06577987

First seen Oct 31, 2025 · Last updated May 08, 2026 · Updated 31 times

Summary

This early-phase study tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors. It is a first-in-human trial, so the main focus is on safety and finding the right dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Comprehensive Cancer Centers of Nevada

    RECRUITING

    Las Vegas, Nevada, 89169, United States

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Florida Cancer Specialists

    RECRUITING

    Sarasota, Florida, 34232, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • NEXT Oncology

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Oregon Health and Science University

    RECRUITING

    Portland, Oregon, 97239, United States

  • START Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • START Mountain

    RECRUITING

    West Valley City, Utah, 84119, United States

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • UH Seidman Cancer Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

Conditions

Explore the condition pages connected to this study.